Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 27, 2004. The report details a share repurchase transaction executed on August 26, 2004, and updates regarding directors' interests in company shares and employee benefit plans.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial data disclosed relates to the share buyback:
- Shares Purchased: 1,000,000 Ordinary shares.
- Purchase Price: 1,121.43 pence per share.
- Treasury Holdings: 38,868,000 shares held in Treasury following the transaction.
- Shares in Issue: 5,895,305,474 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through a buyback authorized at the Annual General Meeting on May 17, 2004. Additionally, there were minor adjustments in directors' interests due to:
- Transfers of 78,854 Ordinary Shares from the GlaxoSmithKline Employee Trust to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- A decrease in Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan from 19,176,895 to 19,127,076 due to fund movements.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total cost of the 1,000,000 share repurchase against the stated price of 1,121.43 pence.
- Confirm the updated total share count (5,895,305,474 in issue) in subsequent filings.
- Review the impact of the 38,868,000 Treasury shares on earnings per share calculations in future reports.
- Monitor the GlaxoSmithKline Employee Trust and US Retirement Savings Plan for further director interest disclosures.